HCW Biologics Inc. (HCWB)

0,6470 +0,0068 (+1,06%) Alla chiusura: 04:00PM EDT

HCW Biologics Inc.

2929 North Commerce Parkway
Miramar, FL 33025
United States
954 842 2024
https://www.hcwbiologics.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 45

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Hing C. Wong Ph.D.	Founder, CEO, Director & Secretary	425,88k	N/D	1954
Ms. Rebecca Byam CPA, M.B.A.	Chief Financial Officer	300,3k	N/D	1956
Dr. Peter Rhode Ph.D.	Chief Scientific Officer & VP of Clinical Operations	251,16k	N/D	1958
Ms. Nicole Valdivieso Esq.	Vice President of Legal Affairs	N/D	N/D	N/D
Ms. Raquel Diaz M.S.	Director of Human Resources	N/D	N/D	N/D
Mr. Lee D. Flowers	Senior Vice President of Business Development	N/D	N/D	1946

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Governance aziendale

L'ISS Governance QualityScore di HCW Biologics Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.